| Market Cap | 15.09B | P/E | 19.47 | EPS this Y | 0.50% | Ern Qtrly Grth | 90.10% |
| Income | 850M | Forward P/E | 14.84 | EPS next Y | 7.50% | 50D Avg Chg | -2.00% |
| Sales | 9.25B | PEG | 2.82 | EPS past 5Y | 9.96% | 200D Avg Chg | -5.00% |
| Dividend | 2.00% | Price/Book | 2.42 | EPS next 5Y | 5.21% | 52W High Chg | -15.00% |
| Recommedations | 2.40 | Quick Ratio | 1.05 | Shares Outstanding | 111.06M | 52W Low Chg | 12.00% |
| Insider Own | 0.43% | ROA | 6.21% | Shares Float | 109.71M | Beta | 0.89 |
| Inst Own | 91.77% | ROE | 14.62% | Shares Shorted/Prior | 2.55M/2.75M | Price | 134.76 |
| Gross Margin | 33.17% | Profit Margin | 9.23% | Avg. Volume | 915,419 | Target Price | 142.29 |
| Oper. Margin | 12.94% | Earnings Date | Apr 23 | Volume | 886,819 | Change | 0.12% |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Truist Securities | Hold | Mar 20, 24 |
| Leerink Partners | Market Perform | Feb 26, 24 |
| Jefferies | Buy | Feb 7, 24 |
| Truist Securities | Hold | Feb 2, 24 |
| Truist Securities | Hold | Dec 20, 23 |
| B of A Securities | Buy | Dec 12, 23 |
| Citigroup | Neutral | Dec 11, 23 |
| UBS | Neutral | Dec 7, 23 |
| JP Morgan | Neutral | Nov 17, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Doherty Catherine T. | SVP, Regional Busine.. SVP, Regional Businesses | Mar 03 | Sell | 140.63 | 717 | 100,832 | 67,810 | 03/06/23 |
| PREVOZNIK MICHAEL E | SVP & General Counse.. SVP & General Counsel | Mar 01 | Sell | 138.54 | 593 | 82,154 | 38,527 | 03/03/23 |
| Doherty Catherine T. | SVP, Regional Busine.. SVP, Regional Businesses | Nov 28 | Option | 86.63 | 40,765 | 3,531,472 | 108,498 | 11/29/22 |
| Doherty Catherine T. | SVP, Regional Busine.. SVP, Regional Businesses | Nov 28 | Sell | 149.14 | 40,765 | 6,079,692 | 67,733 | 11/29/22 |
| DEPPE MICHAEL J | VP, Corp. Controller.. VP, Corp. Controller & CAO | Oct 26 | Option | 54.14 | 15,497 | 839,008 | 47,503 | 10/27/22 |
| DEPPE MICHAEL J | VP, Corp. Controller.. VP, Corp. Controller & CAO | Oct 26 | Sell | 145 | 15,497 | 2,247,065 | 32,013 | 10/27/22 |
| RING TIMOTHY M | Director Director | Sep 01 | Option | 61.23 | 2,000 | 122,460 | 25,933 | 09/06/22 |
| RING TIMOTHY M | Director Director | Sep 01 | Sell | 125.02 | 2,000 | 250,040 | 23,933 | 09/06/22 |
| Doherty Catherine T. | SVP, Group Exec. Cli.. SVP, Group Exec. Clin. Fran. | Feb 24 | Sell | 126.26 | 2,750 | 347,215 | 64,405 | 02/28/22 |
| PREVOZNIK MICHAEL E | SVP & General Counse.. SVP & General Counsel | Feb 24 | Sell | 126.26 | 1,669 | 210,728 | 37,144 | 02/28/22 |
| WILENSKY GAIL R | Director Director | Nov 27 | Option | 57.67 | 6,111 | 352,421 | 22,593 | 11/27/20 |
| WILENSKY GAIL R | Director Director | Nov 27 | Sell | 126.02 | 6,111 | 770,108 | 16,482 | 11/27/20 |